EarningsMarch rebounded strongly and exceeded management expectations, with April tracking in line with expectations and a seasonally stronger Q2 anticipated.
Market GrowthGeneDx is focused on level 3 and 4 NICUs with an estimated incremental $800M+ total addressable market, with potential for growth to $1.2B+.
Product InnovationThe ultra-rapid genome was launched, offering a fast turnaround time and competitive pricing, which may help take volumes from smaller competitors.